Peng SL, Thomas M, Ruszkiewicz A, Hunter A, Lawrence M, Moore J. Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE-5 - a population-based study. doi: 10.1007/s0053-6.ĭe Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, et al. Colorectal cancer: Genetics of development and metastasis. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Cercek A, Smith RA, Jemal A. Thus, CMA is a promising predictor of chemosensitivity to 5‑FU treatment and anti‑CMA therapy may be a novel therapeutic option for patients with CRC.Ĭhaperone‑mediated autophagy lysosome‑associated membrane protein 2A colorectal cancer drug resistance NF‑κB p65 pathway 5‑fluorouracil. Taken together, the results of the present study suggested that chemoresistance in patients with CRC may be mediated by enhancing CMA. Accordingly, loss or gain of function of LAMP2A in 5‑FU‑resistant CRC cells rendered them sensitive or resistant to 5‑FU, respectively. High expression of LAMP2A was found to be responsible for 5‑FU resistance and to enhance PLD2 expression through the activation of NF‑κB pathway. In engineered 5‑FU‑resistant CRC cell lines, a significant elevation of lysosome‑associated membrane protein 2A (LAMP2A), which is the key molecule in the CMA pathway, was identified. The present study investigated the mechanisms underlying the response and resistance to 5‑fluorouracil (5‑FU) in colorectal cancer (CRC) cell lines. Chaperone‑mediated autophagy (CMA) is a selective type of autophagy whereby a specific subset of intracellular proteins is targeted to the lysosome for degradation.
0 kommentar(er)
